Karen Canfell (Australia)

Cancer Council New South Wales Cancer Research Division

Presenter of 3 Presentations

 Conference Calendar
Global Supply, Demand, and Pricing for HPV Vaccines and HPV Testing Hall A

Introduction by Chairs (ID 1379)

Session Date
07/24/2020
Session Time
14:15 - 15:20
Room
Hall A
Session Type
Dedicated Symposium
Session Name
Global Supply, Demand, and Pricing for HPV Vaccines and HPV Testing
Lecture Time
14:15 - 14:18
Presenter
Authors

Webcast

[session]
[presentation]
[presenter]
Hide
Elimination Hall A

Overall model and time line to elimination by world region and country economic status (ID 1362)

Session Date
07/24/2020
Session Time
09:00 - 10:05
Room
Hall A
Session Type
Dedicated Symposium
Session Name
Elimination
Lecture Time
09:15 - 09:27
Presenter
Authors

Webcast

[session]
[presentation]
[presenter]
Hide
Public Health / Epidemiology / Vaccination: Implementation, Evaluation and Impact ePoster

MONITORING HPV VACCINE IMPACT IN AUSTRALIA: RESULTS BASED ON COBAS 4800 AND LINEAR ARRAY (ID 761)

Session Date
07/21/2020
Session Time
10:00 - 17:00
Room
ePoster
Session Type
Poster Viewing - 20-24 July
Session Name
Public Health / Epidemiology / Vaccination: Implementation, Evaluation and Impact
Lecture Time
10:53 - 10:54
Presenter
Authors

Abstract

Introduction

Australia introduced HPV vaccination in 2007 and the cervical screening program transitioned to primary HPV testing with genotyping for HPV 16/18 in 2017, opening up the possibility of using routine screening data to monitor the impact of HPV vaccination. Compass is a major RCT of HPV vs cytology screening acting as a sentinel experience for the new screening program. We investigated the impact of HPV vaccination in women ≥25 years and compared pre- and-post-vaccination HPV prevalence estimates using different technologies for HPV testing.

Methods

We used Australian pre-vaccination (2005-7) HPV prevalence Linear Array (LA) data from WHINURS (1933 samples) and post-vaccination (2014) LA data from Compass pilot (2,991 samples) to estimated vaccine impact on oncogenic HPV prevalence. We also compared post-vaccination HPV prevalence estimates with LA vs cobas 4800 (i.e. clinical HPV testing) from Compass.

Results

Using the LA data, the ratio between other high risk (OHR) types and HPV 16/18 prevalence (OHR-HPV:HPV16/18) at ages 25-34/35-44/45-55/56-64 years was 1.65; 3.47; 2.29; 3.50, respectively, for WHINURS (pre-vaccination) and 7.46; 2.52; 2.55;1.83, respectively, for Compass (post-vaccination). In the 25-34 age group absolute prevalence dropped from 10.3% to 1.8% for HPV 16/18 (p<0.001). Comparable prevalence ratios (OHR-HPV:HPV 16/18) were also observed between cobas and LA for Compass except for the 55-64 year group; [cobas (OHR-HPV:HPV 16/18): 7.92; 2.81; 2.33; 9.00 for 25-34/35-44/45-54/55-64 year groups, respectively; LA (see above)]. [Absolute HPV (16/18) prevalence, cobas:1.7%/1.6%/1.1%/0.2% for 25-34/35-44/45-54/55-64 year groups, respectively, vs. LA:1.8%/2.2%/1.4%/1.1%, respectively; and OHR-HPV, cobas:13.3%/4.6%/2.6%/1.7% for 25-34/35-44/45-54/55-64 year groups, respectively vs. LA:13.3%/5.7%/3.5%/2.1% respectively].

Conclusions

The marked reduction in vaccine-targeted HPV 16/18 infections in women aged 25-34 years indicates the substantial impact of HPV vaccination. Similar prevalence estimates between cobas and LA support the potential use of data from HPV screening programs for long-term monitoring of infection prevalence in screened women.

Hide

Moderator of 1 Session

 Conference Calendar
Dedicated Symposium

01040 - Global Supply, Demand, and Pricing for HPV Vaccines and HPV Testing (ID 65)

Session Type
Dedicated Symposium
Session Date
07/24/2020
Session Time
14:15 - 15:20
Room
Hall A
Chair(s)

Session Webcast